Evidence map›Paper›PMID 34171164›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2021

Risk factors for the delayed viral clearance in COVID-19 patients.

Xiaoping Chen, Wenjia Hu Mt, Miao Yang, Jiaxin Ling, Yongxi Zhang, Liping Deng, Jinlin Li, Åke Lundkvist, Johanna F Lindahl, Yong Xiong

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Article
  3. The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  4. Review
  5. Review
  6. Article
  7. Risk factors for the delayed viral clearance in COVID-19 patients.Journal of clinical hypertension (Greenwich, Conn.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Xiaoping ChenDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wenjia Hu MtDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
Miao YangDepartment of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jiaxin LingDepartment of Medical Biochemistry and Microbiology, Zoonosis Science Center, University of Uppsala, Uppsala, Sweden.
Yongxi ZhangDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
Liping DengDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jinlin LiDepartment of Medical Biochemistry and Microbiology, Zoonosis Science Center, University of Uppsala, Uppsala, Sweden.
Åke LundkvistDepartment of Medical Biochemistry and Microbiology, Zoonosis Science Center, University of Uppsala, Uppsala, Sweden.
Johanna F LindahlDepartment of Medical Biochemistry and Microbiology, Zoonosis Science Center, University of Uppsala, Uppsala, Sweden.
Yong XiongDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0003-0678-4064
Wuhan University · CNUppsala University · SE

Funding

Fundamental Research Funds for the Central Universities 2042020kf1018
6 · The paper itself

Abstract

Comorbidities are important for the disease outcome of COVID-19, however, which underlying diseases that contribute the most to aggravate the conditions of COVID-19 patients are still unclear. Viral clearance is the most important laboratory test for defining the recovery of COVID-19 infections. To better understand which underlying diseases that are risk factors for delaying the viral clearance, we retrospectively analyzed 161 COVID-19 clinical cases in the Zhongnan Hospital of Wuhan University, Wuhan, China between January 5 and March 13, 2020. The demographic, clinical and laboratory data, as well as patient treatment records were collected. Univariable and multivariable analysis were performed to explore the association between delayed viral clearance and other factors by using logistic regression. Survival analyses by Kaplan-Meier and Cox regression modeling were employed to identify factors negatively influencing the viral clearance negatively. We found that hypertension and intravenous immunoglobulin adversely affected the time of viral RNA shedding. Hypertension was the most important risk factor to delay the SARS-CoV-2 virus clearance, however, the use of Angiotensin-Converting Enzyme Inhibitors(ACEI)/Angiotensin Receptor Blockers(ARB) did not shorten the time for virus clearance in these hypertensive patients' virus clearance. We conclude that patients having hypertension and intravenous immunoglobulin may delay the viral clearance in COVID-19 patients.

Indexed as

COVID-19HypertensionAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansRetrospective StudiesRisk FactorsSARS-CoV-2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCOVID-19hypertensionrisk factorsSARS-CoV-2viral clearance

Identifiers

PMID34171164
PMCPMC8420571
OpenAlexW3176468524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.